AMGEN Pharmaceutical Jobs

PharmaDiversityJobBoard-Diversity Job Board connecting diversity & minority job seekers with Pharmaceutical jobs.

Home | Job Seekers | Employers | FAQ | Contact Us You're not logged in!

Translate:

AMGEN Jobs

Click links to read Current News for this Featured Employer Amgen to Present at 18th Annual Credit Suisse Healthcare Conference | Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer Phase 3 Results Reinforce Importance of KRAS Status | Call for Applications: The Amgen Award for Science Teaching Excellence 34 Outstanding Teachers Will Be Recognized in Communities Where Amgen Operates | Amgen Announces Webcast of 2009 Third Quarter Financial Results | 200 Cyclists to Ride in Arthritis Foundation's Amgen California Coast Classic Bike Tour to Raise $1 Million Cyclists from across the country will bike down the California coast to raise funds and help those affected by arthritis | Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer | Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer | Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients | Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases | Amgen to Present at the UBS Global Life Sciences Conference | Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress Key Denosumab and Vectibix(R) (Panitumumab) Data to be Presented | Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting | Amgen to Present at the Thomas Weisel Healthcare Conference | Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes No Statistically Significant Difference in Cardiovascular and Renal Composite Endpoints Between Aranesp and Placebo | Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer Second Prospective Phase 3 Vectibix Combination Chemotherapy Trial to Show Progression-Free Survival Advantage in KRAS Wild-Type Population | Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer Pivotal Study Meets Primary Endpoint of Progression-Free Survival in Wild-Type KRAS Population Phase 3 Results Reinforce Importance of KRAS Testing | Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R) Second of Three Pivotal Phase Three Bone Metastases Trials Meets Primary EndpointDenosumab Delayed Time to Skeletal Related Events | Economy Is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease - National Census Data Shows Osteoporosis Rates to Increase by an Estimated 30(1) Percent Among D.C. Residents by 2020 -- Special Council of Health and Women's Groups Formed to Encourage Women to Make Bone Health a Priority Before They Break a Bone - | Amgen Announces Webcast of 2009 Second Quarter Financial Results | New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure in Patients With Chronic ITP | Amgen Highlights Data to Be Presented at ASCO | Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference | Amgen Announces Voting Results Of Annual Meeting Of Stockholders | Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08 | Amgen Announces Webcast of 2009 First Quarter Financial Results | Amgen to Present at the Citigroup Biotech Day | Amgen to Present at the Barclays Capital Global Healthcare Conference | FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab | Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | AMDL Chairman & CEO Mr. Douglas MacLellan Featured on Fox Business News Monday February 2, 2009 | Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 | Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results | Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients | Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union | Amgen Positioned to Deliver Attractive Growth Over Next Five Years | Call for Applications: The Amgen Award for Science Teaching Excellence | Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York | Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 | 240 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.1 Million for Arthritis Foundation |

Save	Date	Job Title	City Country	Company Name	Pay
Items 1-25/338 displayed. [1-25][26-50][51-75][76-100][101-125][126-150][151-175][176-200][201-225][226-250] next
	Nov 19	Scientist - Medicinal Chemistry (UR) - Thousand Oaks, CA - NB50999798 Research	Any, US	AMGEN	Not specified
	Nov 19	Sr Mgr GRAAS Operations Thousand Oaks CA NB51000031 Regulatory/Compliance/Safety	Any, US	AMGEN	Not specified
	Nov 19	Administrative Coordinator Thousand Oaks, California NB50992822 Administrative	Any, US	AMGEN	Not specified
	Nov 19	Engineering Projects Senior Manager - NC51001954 Engineering/Operations/Plant Facilities	Any, US	AMGEN	Not specified
	Nov 19	Senior Biopharmaceutical Rep NC51001957 Sales	Any, US	AMGEN	Not specified
	Nov 19	Senior Biopharmaceutical Rep NC51001958 Sales	Any, US	AMGEN	Not specified
	Nov 19	Senior Biopharmaceutical Rep NC51001959 Sales	Any, US	AMGEN	Not specified
	Nov 19	Regulatory Affairs Manager, International Expansion NC51002831 Regulatory/Compliance/Safety	Any, US	AMGEN	Not specified
	Nov 19	Sr Project Manager, International Expansion, Reg Affairs NC51002861 Regulatory/Compliance/Safety	Any, US	AMGEN	Not specified
	Nov 19	Clinical Research Medical Dir NB51002676 Clinical Development	Any, US	AMGEN	Not specified
	Nov 19	Regulatory Affairs Mgr_ NC51003363 Regulatory/Compliance/Safety	Any, US	AMGEN	Not specified
	Nov 19	Associate Customer Service (Belgium/Nordics) - NC51003556 Sales and Marketing Operations	Any, US	AMGEN	Not specified
	Nov 19	Therapeutical Area Leader (Med. Development SR Manager) NC50999534 Medical Affairs	Any, US	AMGEN	Not specified
	Nov 19	Senior Biopharmaceutical Rep NC50995787 Sales	Any, US	AMGEN	Not specified
	Nov 19	Principal Engineer NB50993337 Process Development	Any, US	AMGEN	Not specified
	Nov 19	Senior Biopharmaceutical Rep NC50995786 Sales	Any, US	AMGEN	Not specified
	Nov 19	Senior Biopharmaceutical Rep NC50991138 Sales	Any, US	AMGEN	Not specified
	Nov 19	Research Operations Manager, Thousand Oaks, CA - NB50976167 Project Management	Any, US	AMGEN	Not specified
	Nov 19	Regional Medical Liaison NB50953224 - Oncology - Des Moines, IA Medical Affairs	Any, US	AMGEN	Not specified
	Nov 19	Scientist - Analytical Chemistry - Thousand Oaks, CA - NB50907865 Research	Any, US	AMGEN	Not specified
	Nov 19	Product Manager (Russia) NC50897634 Marketing	Any, Russian Federation	AMGEN	Not specified
	Nov 19	Sr Biopharmaceutical Rep, Oncology - Utah (Greater Salt Lake area) - NB50867853 Sales	Any, US	AMGEN	Not specified
	Nov 19	Sr. Medical Advisor, Oncology NC50480774 Medical Affairs	Any, Canada	AMGEN	Not specified
	Nov 17	Sr Biopharmaceutical Representative, Inflammation - Kansas City, MO NB50999441 Sales	Any, US	AMGEN	Not specified
	Nov 17	Competitive Intelligence Sr. Manager, BAI - Thousand Oaks, CA - NB50999790 Sales and Marketing Operations	Any, US	AMGEN	Not specified